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In cytotoxic T cells (CTL), Akt, also known as protein
kinase B, is activated by the T cell antigen receptor
(TCR) and the cytokine interleukin 2 (IL-2). Akt can
control cell metabolism in many cell types but
whether this role is important for CTL function has
not been determined. Here we have shown that Akt
does not mediate IL-2- or TCR-induced cell meta-
bolic responses; rather, this role is assumed by other
Akt-related kinases. There is, however, a nonredun-
dant role for sustained and strong activation of Akt
in CTL to coordinate the TCR- and IL-2-induced tran-
scriptional programs that control expression of key
cytolytic effector molecules, adhesion molecules,
and cytokine and chemokine receptors that distin-
guish effector versus memory and naive T cells. Akt
is thus dispensable for metabolism, but the strength
and duration of Akt activity dictates the CTL tran-
scriptional program and determines CTL fate.
INTRODUCTION
Cytotoxic T cells that express CD8 and recognize peptide-class
I major histocompatibility complexes play a key role in immunity.
The transcriptional program that determines the effector or
memory fate of CTL is controlled by the TCR and cytokines. In
particular, interleukin-2 (IL-2), amember of the common cytokine
receptor gamma-chain (gc) family of cytokines, has a key role to
maintain antigen-specific effector and memory CD8+ T cells
during viral infections (Bachmann et al., 2007; D’Souza and Le-
franc¸ois, 2003; Kalia et al., 2010; Malek and Castro, 2010;
Williams et al., 2006). IL-2 is important for CTL because it can up-
regulate glucose and nutrient uptake in a response that
increases cellular energy production in order to support the
biosynthetic demands of rapid cell division and effector function
(Cornish et al., 2006; Maciver et al., 2008). However, IL-2 also
directs the transcriptional program of CTL and promotes effector
CTL differentiation at the expense of memory cell formation (Ka-
lia et al., 2010; Obar et al., 2010; Pipkin et al., 2010).
IL-2 acts via a receptor complex consisting of the common
gamma chain (gc), a b subunit (CD122), and CD25. Triggering224 Immunity 34, 224–236, February 25, 2011 ª2011 Elsevier Inc.of the IL-2 receptor stimulates the Janus family kinases Jak1
and Jak3 and induces the tyrosine phosphorylation and DNA
binding of STAT (signal transducer and activator of transcription)
family transcription factors STAT5 and STAT3. The activation of
STAT5 is important for IL-2 signaling (Malek and Castro, 2010)
but is not sufficient to mimic the effects of IL-2 on T cell biology.
In this context, IL-2 induces sustained accumulation of phospha-
tidylinositol 3,4,5-trisphosphate (PI(3,4,5)P3), the product of
phosphatidylinositol 3-kinases (PI3K) (Cornish et al., 2006;
Sinclair et al., 2008), and activates a cascade of serine-threonine
kinases. These include Akt (protein kinase B [PKB]) (Waugh et al.,
2009) and other members of the protein kinase A/G/C-related
(AGC kinase) family including p70 ribosomal S6 kinases (S6Ks)
and p90 ribosomal S6 kinase (RSK) (Lin et al., 2008). The proper
balance of Akt and STAT5 signaling seems to be critical for virus-
specific CD8+ T cells (Hand et al., 2010). However, the precise
role of Akt in the transcriptional programs that direct effector
CD8+ T cell differentiation has not been explored.
The coordination of glucose metabolism is essential for T cell
activation (Cham et al., 2008; Maciver et al., 2008) and this func-
tion might be controlled by PI3K-Akt. This assumption stems
partly from extrapolating data from thymus studies, where it is
clear that PI3K and Akt control glucose uptake and the expres-
sion of amino acid transporters and transferrin receptors in
T cell progenitors (Juntilla et al., 2007; Kelly et al., 2007; Mao
et al., 2007). Further support for a tropic role for PI3K-Akt in
peripheral T cells come from experiments with PI3K inhibitors,
which prevent Akt activation and prevent increases in both
glucose uptake and amino acid uptake by activated peripheral
T cells (Cornish et al., 2006). However, there are caveats
because some of the PI3K inhibitors used in early T lymphocyte
studies (Cornish et al., 2006) have off-target effects (Bain et al.,
2007). In this context, evidence for Akt-independent pathways
that control T cell metabolism and proliferation are emerging
(Bayascas, 2008; Finlay et al., 2009; Jacobs et al., 2008). More-
over, constitutively active Akt can stimulate promote cell growth
and survival of CD4+ T cells but not CD8+ T cells (Hand et al.,
2010; Rathmell et al., 2003; Saibil et al., 2007), indicating that
Akt may not have an obligate role to control metabolism in all
T cell subpopulations. Accordingly, the focus of the present
study is the role of PI3K-Akt in TCR and IL-2 regulation of CTL
biology. The data have established that PI3K- and Akt-indepen-
dentmechanisms control CTLmetabolism, survival, and prolifer-
ation but there is a seminal role for Akt signaling in CTL to direct
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RESULTS
p110d Couples the IL-2 Receptor to Akt but
IL-2-Mediated T Cell Proliferation Is p110d Independent
TCR-primed CD8+ T cells cultured in IL-2 clonally expand and
differentiate to effector cytotoxic T cells (CTL) (Manjunath
et al., 2001). This model mimics the in vivo situation where sus-
tained IL-2 signaling promotes the production of terminally
differentiated effector cytotoxic T cells (Kalia et al., 2010; Malek
and Castro, 2010; Pipkin et al., 2010). IL-2 strongly activates Akt
and antigen-experienced T cells cultured in IL-2 contain high
amounts of Akt phosphorylated on the 3-phosphoinositide-
dependent kinase 1 (PDK1) substrate site T308 (Figure 1A).
The TCR activates Akt via a PI3K complex that contains the
p110d catalytic subunit (Garc¸on et al., 2008). Figure 1A shows
that p110d PI3K also coupled the IL-2 receptor to Akt. Hence,
T cells with wild-type p110d substituted with a catalytically inac-
tive mutant, p110dD910A, do not phosphorylate Akt T308 in
response to IL-2 and thus lack Akt activity as judged by the
loss in phosphorylation of Foxo transcription factors (Figure 1A).
The sustained proliferation and survival of antigen-primed CTL
is dependent on exogenous IL-2 (Figure 1B). However, activated
p110dD910A-expressing T cells proliferated normally to IL-2 (Fig-
ure 1C). Further experiments examined the impact of a p110d
inhibitor, IC87114, on IL-2-induced Akt activity in antigen-acti-
vated P14 TCR transgenic T cells. Triggering of the TCR
expressed on these cells with a peptide from the lymphocytic
choriomeningitis virus (LCMV), glycoprotein gp33-41, presented
by the MHC class I molecule H-2Db, followed by clonal expan-
sion in IL-2, generated a homogenous population of CTL. The
exposure of IL-2-maintained P14 CTL to IC87114 caused loss
of Akt T308 phosphorylation (Figure 1D) but did not prevent
T cell proliferation (Figure 1E).
To explore further the role of Akt in IL-2 proliferative
responses, a set of experiments with AktI, a selective allosteric
inhibitor of all three isoforms of Akt, were performed. AktI
prevents the essential PDK1-mediated phosphorylation of Akt
on T308 (Green et al., 2008). The addition of AktI to CTL caused
loss of Akt T308 phosphorylation and a resultant loss of Akt
activity as judged by the loss in phosphorylation of the
Akt substrates Foxo1 and Foxo3a (Figure 1F). However, AktI
did not prevent IL-2-induced proliferation of the CTL nor did it
cause cell death (Figure 1G). Hence, CTL do not need active
Akt to proliferate and survive.
PDK1 Is Required for T Cell Proliferation
One explanation for the Akt independence of IL-2-induced prolif-
eration is that other members of the AGC family of kinases might
compensate for loss of Akt function. We therefore examined the
impact of deleting the gene encoding PDK1, Pdpk1, on IL-2
signal transduction. PDK1 phosphorylates and activatesmultiple
AGC kinases such as RSK and S6K1 in a response that is inde-
pendent of PI(3,4,5)P3 production (Bayascas, 2008). Pdpk1 dele-
tion is thus a strategy that simultaneously inactivates Akt- and PI
(3,4,5)P3-independent AGC kinases in T cells (Kelly et al., 2007).
Accordingly, mice expressing floxed Pdpk1 alleles (Pdpk1fl/fl)were backcrossed with C57BL/6-GT(ROSA)26tm9 (creEsr1) Arte
mice (TamoxCre) that express a tamoxifen-regulated Cre recom-
binase in the ROSA locus. Pdpk1fl/fl TamoxCre CTL were then
generated and treatedwith 4-hydroxytamoxifen (4OHT) to delete
the floxed Pdpk1 alleles. Pdpk1 deletion in 4OHT-treated
Pdpk1fl/fl TamoxCreCTL was confirmed (Figure 2A). Importantly,
immunoblot analysis also revealed that 4OHT-treated Pdpk1fl/fl
TamoxCre CTL had lost phosphorylation of RSK on the PDK1
target site S227 and had lost phosphorylation of Akt on the
PDK1 target site T308. The loss of Akt and S6K1 catalytic activity
was judged by the loss of phosphorylated Foxos and the ribo-
somal S6 subunit (Figure 2B).
Pdpk1 deletion in CTL thus eliminated the activity of multiple
AGC kinases. We therefore assessed the ability of IL-2 to sustain
survival and proliferation of Pdpk1-null cells. Figure 2C shows
that Pdpk1-null CTL failed to proliferate in response to IL-2.
However, whereas IL-2 deprivation resulted in rapid cell death
of CTL (Figure 1B), the loss of PDK1 did not cause cell death (Fig-
ure 2D). PDK1 is thus essential for IL-2-induced T cell prolifera-
tion but not for cell survival.
IL-2 and PDK1 but Not Akt Sustain Glucose Uptake
in CTL
In many cells Akt controls cell proliferation because it maintains
glucose metabolism. In this context, as naive CD8+ T cells
respond to cognate antigen and differentiate to CTL, they
increase glucose uptake and become highly glycolytic. Glucose
uptake in CTL was not autonomous but depended on the provi-
sion of exogenous IL-2 (Figure 3A). Moreover, the importance of
glucose uptake for T cell proliferation was easily demonstrated:
lowering of exogenous glucose concentrations severely
impaired IL-2-induced proliferative responses (Figure 3B). That
glucose deprivation but not Akt inhibition prevented IL-2-
induced CTL proliferation argues that Akt activity is not required
for IL-2-driven glucose uptake. Figure 3C addresses this point
and shows that loss of Akt activity had no impact on the ability
of IL-2-cultured CTL to take up glucose. The Akt independence
of IL-2-induced T cell proliferation can thus be explained by the
ability of IL-2 to maintain glucose uptake via Akt-independent
pathways. We then assessed whether PDK1 plays a role in
IL-2-induced glucose uptake. Figure 3D shows that PDK1-null
T cells had a strikingly reduced rate of glucose uptake but no
defects in amino acid uptake (Figure 3E). Hence PDK1, but not
Akt, is essential for IL-2 control of glucose uptake.
The Akt independence of IL-2-induced glucose uptake raised
the question whether Akt activity was required for the initial
increase in glucose metabolism initiated by the TCR in CD8+
T cells. Figure 3F shows that TCR triggering stimulated a large
increased glucose uptake and this was unimpaired in cells
treated with the Akt inhibitor AktI or the PI3K p110d inhibitor
IC87114. The regulation of glucose uptake via the T cell antigen
receptor in CD8 T cells is thus not mediated by Akt.
PDK1 and Akt Transcriptional Programs in CTL
If Akt is not essential for glucose uptake or IL-2-mediated T cell
survival or proliferation, what does it do? This question is impor-
tant because sustained IL-2 signaling is required tomaintain CTL
effector function both in vitro and in vivo (Kalia et al., 2010; Pipkin
et al., 2010) and there is clearly the potential for Akt to mediateImmunity 34, 224–236, February 25, 2011 ª2011 Elsevier Inc. 225
Figure 1. Akt Is Not Necessary for IL-2-Driven Survival or Proliferation in CTL
(A) Immunoblot analysis of Akt T308 and Foxo1 T24, Foxo3a T32 phosphorylation in wild-type (C57/BL6) and p110dD910A-expressing (Pik3cdD910A) splenic T cells
activated with 2C11 for 48 hr then cultured in IL-2 for 3 days.
(B) Wild-type splenic T cells were activated with 2C11 for 48 hr then cultured in IL-2 for 5 days, with some cells being deprived of IL-2 for the last 24 hr of culture.
Data show fold change in cell number over the last 24 hr of culture and the cell FSC and SSC profiles at the end of the experiment. Gates indicate dead (left) and
viable (right) cell populations.
(C) Splenic T cells fromwild-type and p110dD910A-expressingmice (Pik3cdD910A) were cultured as in (A). Data show fold change in cell number over the last 48 hr of
culture.
(D) Western blot analysis of Akt T308 phosphorylation in P14 T cells activated with gp33 for 48 hr then cultured in IL-2 for 5 days, with IC87114 or LY294002 being
added for the last 48 hr of culture.
(E) P14 T cells were activated with gp33 for 48 hr then cultured in IL-2 for 5 days, with IC87114 added for the last 48 hr of culture. Alternatively, IL-2 was removed
from the culture for the last 48 hr. Data show fold change in cell number over last 48 hr of culture.
(F and G) Wild-type splenic T cells activated with 2C11 for 48 hr cultured in IL-2 for 5 days, with AktI being added for the last 48 hr of culture. Data show (F) immu-
noblot of Akt T308 and Foxo1 T24, Foxo3a T32 phosphorylations and (G) FSC and SSC profiles of cells at the end of the culture plus fold change in cell number
during the last 48 hr of culture.
Data are representative of 3 (A, C–F), 7 (B), or 11 (G) experiments; mean ± SEM of biological replicates.
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metrix microarray analysis to transcriptionally profile Pdpk1-
null and Akt-inhibited CTL. Approximately 9400 annotated genes
were expressed in CTL, and the impact of PDK1 loss or Akt inhi-
bition was revealed by a decrease in the expression of less than226 Immunity 34, 224–236, February 25, 2011 ª2011 Elsevier Inc.2%–3% of these transcripts and an increase in the expression of
another 3%–4% (Tables S1 and S2 available online).
We first looked for non-Akt-dependent, PDK1-regulated
genes to understand why PDK1 but not Akt is required for IL-
2-induced T cell proliferation. Selected genes controlled only
Figure 2. PDK1 Maintains IL-2-Driven Proliferation
(A and B) Immunoblot analysis of (A) PDK1 expression and (B) phosphoryla-
tion of Akt, Foxo1 and Foxo3a, RSK, and small ribosomal subunit S6 in
Pdpk11fl/fl /tm9(creEsr1)Arte (Pdpk1fl/fl TamoxCre) and Pdpk1+/+/ tm9(creEsr1)Arte
(Pdpk1WT/WT TamoxCre) T cells activated with 2C11 for 2 days and then
cultured in IL-2 for 5 days, supplemented as indicated with 4OHT for the final
72 hr of culture.
(C and D) Fold change in cell number over the last 48 hr of culture (C) and FSC
and SSC profiles (D) of 4OHT-treated cells from (A), gates indicate dead (left)
and viable (right) cell populations.
Data are representative of three (A, B) or five (C, D) experiments; mean ± SEM
of biological replicates.
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particular note, PDK1 controlled expression of hexokinase 2,
and hexokinases play a key role in effective uptake of exogenous
glucose. We also used the NIAID DAVID website (http://david.
abcc.ncifcrf.gov) to mine the gene ontology terms (GO) associ-
ated with the PDK1-controlled genes. We noted that GO terms
related to lipid and cholesterol metabolism (Figure 4B) werestrongly overrepresented in this list, indicating that PDK1 but
not Akt controls lipid metabolism in CTL.
We next interrogated the data to characterize genes coregu-
lated by PDK1 and Akt. One clear result was that Akt inhibition
or Pdpk1 deletion resulted in the re-expression of Foxo target
genes (Figure 4C), including the IL-7 receptor a subunit
(CD127), the transcription factor Klf2, and its targets L-selectin
(CD62L), CC motif chemokine receptor 7 (CCR7), and sphingo-
sine-1-phosphate receptor 1 (S1P1) (Carlson et al., 2006; Fabre
et al., 2008; Kerdiles et al., 2009; Ouyang et al., 2009). Figures 4D
and 4E used quantitative polymerase chain reaction (PCR) anal-
ysis to verify these changes. IL-2 activation of Akt is dependent
on PI3K p110d (Figure 1), so it would be predicted that inactivat-
ing p110d would also restore expression of the Foxo-regulated
genes in CTL. Indeed, IL-2-cultured CTL expressing catalytically
inactive p110d (Pik3cdD910A) maintained high expression of Klf2
andCD62L, CCR7, and S1P1 (Figure 4F). Moreover, treatment of
CTL with the p110d inhibitor IC87114 drove re-expression of Klf2
and its targets (Figure 4G).
Inhibition of PI3K p110d and Akt Reprograms CTL
Trafficking
Deletion of Pdpk1 or the inhibition of Akt caused CTL to re-
express CD62L and CCR7 (Figures 4C–4E). CD62L controls
T cell adhesion to the endothelium of high endothelial venules
and CCR7 directs migration of T cells into lymphoid organs.
Moreover, the loss of CD62L and CCR7 by CTL is part of the
program that directs the trafficking of CTL away from lymphoid
tissue. The re-expression of CD62L and CCR7 in CTL deleted
of Pdpk1 or exposed to AktI could argue that inhibition of Akt
might reprogram the trafficking of CTL and restore their ability
to transmigrate from the blood into secondary lymphoid tissue.
In this context, strong activation of PI3K and Akt is required
and sufficient to downregulate the ability of naive T cells to
home to secondary lymphoid tissue in vivo (Finlay et al., 2009;
Waugh et al., 2009). It is also known that p110d activity is
required for T cells to exit lymphoid tissue and home to sites of
infection (Liu and Uzonna, 2010). T cells thus appear to need
to activate Akt to exit lymphoid tissues. However, it is not known
whether inhibition of Akt is sufficient to reprogram the ability of
CTL to home to lymphoid tissue. In this context, inhibition of
Akt had pleiotropic effects on the expression of multiple adhe-
sion molecules and chemokine receptors by CTL and was not
limited to controlling CD62L and CCR7 expression (Figure 5A).
To directly test the impact of Akt inhibition on CTL trafficking,
in vivo adoptive transfer experiments were performed comparing
the ability of wild-type CTL or CTL pretreated with either AktI or
the p110d inhibitor IC87114 to home from the blood to lymphoid
tissue. Strikingly, CTL pretreated with either AktI or IC87114
showed strong preferential homing to lymph nodes and spleen
compared to wild-type CTL (Figures 5B and 5C). Sustained acti-
vation of Akt is thus required to maintain the trafficking charac-
teristics of CTL: Loss of p110d catalytic activity or Akt inhibition
reprograms the ability of CTL to traffic to lymphoid tissue.
To further explore the in vivo role of Akt in CD8 T cell trafficking
responses, we compared in vivo immune responses of wild-type
and Pdpk1K465E/K465E T cells. The K465E mutation creates
a PDK1 molecule with a mutated PH domain that cannot bind
PI(3,4,5)P3 and can support only a low amount of Akt activityImmunity 34, 224–236, February 25, 2011 ª2011 Elsevier Inc. 227
Figure 3. IL-2 and PDK1 but Not Akt Sustain Glucose Uptake in CTL
(A) 2-deoxyglucose (2DOG) uptake bywild-type splenic T cells activated with 2C11 for 48 hr and then cultured in IL-2 for 5 days, with some cells being deprived of
IL-2 for the last 24 hr of culture.
(B)Wild-type splenocytes were activatedwith 2C11 and IL-2 for 2 days and then cultured in IL-2 in standardmedia for 72 hr. For the final 48 hr of culture, cells were
placed in media containing indicated glucose concentrations and the fold change in cell number assessed.
(C) Relative 2DOG uptake in wild-type splenic T cells activated with 2C11 for 48 hr then cultured in IL-2 for an additional 5 days, with 1 mMAktI being added for the
last 48 hr of culture.
(D and E) Relative 2DOG uptake (D) and phenylalanine uptake (E) by Cre control (Pdpk1+/+/ tm9(creEsr1)Arte +4OHT) and Pdpk1-null (Pdpk1fl/fl/ tm9(creEsr1)Arte +4OHT)
CTL.
(F) Naive P14 T cells were maintained in IL-7 or stimulated for 18 hr with gp33 in the presence or absence of AktI or IC87114 and then their ability to take up 2DOG
was assayed.
Data are representative of 3 (B, D, F), 5 (A), or 11 (C) experiments; mean ± SEM of biological replicates, except (F), representative data from 2 experiments;
mean ± SD of technical replicates.
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K465E T cells proliferated in vivo in response to immunization
with cognate antigen and lipopolysaccharide (LPS). However,
K465E T cells failed to downregulate CD62L (Figure 5E) and
were retained in lymphoid tissue (Figure 5F) compared to control
effector CD8+ T cells.
Akt Is Necessary to Induce and Sustain Expression
of CTL Effector Molecules
A key role for IL-2 in CD8+ T cells is to promote effector differen-
tiation of CTL by driving expression of cytolytic effector mole-
cules and by controlling the cytokine receptor profile of CTL
(Janas et al., 2005; Pipkin et al., 2010). It was therefore striking
that inhibition of Akt caused a decrease in the expression of
mRNA encoding several molecules critical for CTL effector func-
tion (Figure 6A), notably multiple granzymes, Fas ligand, the
cytolytic effector perforin, and interferon gamma (IFN-g). It was
equally notable that Akt inhibition had a considerable impact228 Immunity 34, 224–236, February 25, 2011 ª2011 Elsevier Inc.on the transcription of key cytokine receptors. Akt inhibition
thus decreased expression of mRNA encoding IL-12 receptor
b-chains while simultaneously increasing expression of mRNA
encoding IL-6 receptors and CD27 (TNFRSF7), the CD70
coreceptor (Figure 6B). The role of Akt in perforin and IFN-g
expression was verified by real-time PCR analysis, ELISA, and
immunoblot analysis (Figure 6C). Akt inhibition thus caused
loss of IFN-g mRNA expression and prevented IFN-g protein
production. Similar results were obtained after the deletion of
Pdpk1 from CTL (Figure 6D), providing genetic evidence that
PDK1-Akt signaling sustains perforin and IFN-g protein expres-
sion in CTL.
Akt is also rapidly activated in CD8+ T cells in response to trig-
gering of the TCR. Akt is not required for TCR-induced metabolic
programs (Figure 3F), but is it necessary for the TCR to initiate
expression of CTL effector molecules? In these experiments
we focused on the induction of IFN-g because this cytokine
can be induced rapidly in response to triggering of the TCR in
Figure 4. PDK1 and Akt Regulation of the CTL Transcriptional Program
Pdpk1-null (Pdpk1fl/fl/ tm9(creEsr1)Arte +4OHT) and Cre control (Pdpk1+/+/ tm9(creEsr1)Arte +4OHT) CTL were generated and their transcriptional profiles compared via
microarray. Analysis was performed with cells from three age- and sex-matched mice for each genotype. In a separate experiment, three wild-type (C57/BL6)
age- and sex-matchedmicewere used to generate CTL by activating wild-type splenocyteswith 2C11 for 48 hr with IL-2 then culturing the cells in IL-2 for a further
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shown that p110d is required for TCR-induced IFN-g production
during immune activation but the role of Akt has not been ad-
dressed (Liu and Uzonna, 2010; Soond et al., 2010). We found
that inhibition of Akt suppressed TCR induction of IFN-g mRNA
and protein in both naive CD8+ T cells and effector CTL (Figures
7A and 7B). This reflects that Akt activity is important for IFN-g
gene transcription. Figure 7C thus shows that the loss of Akt
activity reduced the amount of RNA polymerase II (Pol II) recruit-
ment to the IFN-g transcription start site and distal exons.
Why is Akt needed for IFN-g production? We considered the
possibility that Akt controlled the activity of mTOR (mammalian
target of rapamycin), which is known to control the expression
of T effector molecules (Rao et al., 2010). However, although
Pdpk1 deletion prevented phosphorylation of the mTOR target
S6 (Figure 2B), inhibition of Akt only weakly suppressed the
phosphorylation of S6 and S6K1 (Figure S1). Akt activity is thus
dispensable for mTOR activation in CTL. Accordingly, an inability
to activate mTOR does not explain why Akt is required for IFN-g
production. However, an important insight as to a possible
mechanism for Akt control of IFN-g production came from
experiments with Pdpk1K465E/K465E T cells that support only
a low level of Akt activity. These T cells have a selective defect
in the phosphorylation and inactivation of Foxo family transcrip-
tion factors and fail to downregulate expression of Foxo gene
targets (Waugh et al., 2009). Foxos can both transactivate and
repress gene expression (Fabre et al., 2008), and in this context,
TCR-induced production of IFN-g is severely attenuated in
Pdpk1K465E/K465E T cells (Figure 7D). This is consistent with
amodel whereby the defects in IFN-g production caused by inhi-
bition of Akt activity in CTL might be caused by relocation of
Foxo transcription factors in the nuclei of T cells that then repress
the IFN-g gene. To assess whether the restoration of Foxos to
the nuclei of TCR-activated T cells would impact on IFN-g
gene expression, we examined IFN-g production in T cells
expressing a GFP-tagged Foxo3a mutant with alanine substitu-
tions at its Akt substrate sequences, T32, S252, and S314
(FoxoAAA). This phospho mutant could restore Foxo transcrip-
tional function in cells expressing active Akt. Figures 7E and 7F
show that activated T cells expressing the FoxoAAA mutant
could not produce IFN-g in response to peptide triggering of
TCR complexes. Akt-regulated nuclear export of Foxo transcrip-
tion factors is thus required for IFN-g production.
DISCUSSION
The objective of the present study was to gain a more in-depth
understanding of the function of PDK1 and Akt in the context
of TCR and IL-2 signal transduction in CD8+ T cells. The
accepted view of Akt is that it controls T cell metabolism.5 days, with 1 mM AktI being added to half of each culture for the last 48 hr. Comp
performed by microarray.
(A) Heat map showing the relative normalized expression of selected genes chan
(B) Gene ontology analysis of genes changing in expression after Pdpk1 loss bu
(C) Heat maps showing the relative normalized expression of Foxo-regulated ge
treated CTL and between Cre control and Pdpk1-null CTL.
(D–G) Real-time PCRmeasurements of relative gene expression levels in (D) Cre c
CTL, (F) wild-type versus PI3K p110dD910A-expressing CTL (Pik3cdD910A), and (G
Data representative of a minimum of three experiments; mean ± SEM of biologic
230 Immunity 34, 224–236, February 25, 2011 ª2011 Elsevier Inc.However, the data herein showed that Akt is not essential for
CD8+ T cell metabolism, survival, or proliferation. Nevertheless,
Akt does have a critical role in CTL function. Akt permits TCR
and IL-2 signaling to maintain the expression of cytolytic effector
molecules and to determine the repertoire of cytokine receptors,
adhesion molecules, chemokine receptors, and effector mole-
cules that distinguish effector and memory CTL populations.
The present results thus force a shift in the accepted paradigm
that Akt functions as an obligate controller of T cell metabolism.
Rather, Akt simultaneously induces and represses expression of
key genes to create an effector CTL, with the Foxo transcription
factors being at the center of this process.
The TCR and IL-2 control the metabolic programs of CTL by
driving glucose uptake, amino acid uptake, and protein
synthesis. The current results show that this metabolic role is
notmediated by Akt but is controlled by PDK1. This kinase phos-
phorylates and activates many AGC family serine kinases
including Akt, PKCs, S6Ks, RSK, and the SGKs (Bayascas,
2008; Williams et al., 2000). These all share similar substrate
specificities and there are numerous examples of redundant
functions between different family members (Juntilla et al.,
2007; Kelly et al., 2007). Importantly, the ability of PDK1 to phos-
phorylate the RSKs and the SGKs is independent of PI3K
signaling (Bayascas et al., 2008; Waugh et al., 2009). Accord-
ingly, PDK1 loss is more global than inhibition of PI(3,4,5)P3
production for terminating AGC kinase activity. The fact that
glucose uptake and proliferation of CTL is PDK1 dependent
rather than Akt dependent thus reveals that there is redundancy
between AGC family kinases in CD8+ T cells. These data also
indicate that PI3K and Akt do not have obligatory functions as
metabolic switches in lymphocytes because other molecules
can assume this role. These include other PDK1-controlled
molecules, but it is also noteworthy that deletion of the serine-
threonine master kinase LKB1 causes death of activated
T cells (Tama´s et al., 2010). There is also evidence that PIM
kinases are important regulators of T cell survival (Fox et al.,
2005). The control of T cell metabolism may thus be determined
by multiple kinases.
Akt may not control CTL metabolism but the data herein shown
that Akt does control a fundamental part of the CTL transcriptional
program. Here it is relevant that cytotoxic T cells have two fates:
they continue to become terminally differentiated ‘‘exhausted’’
effector T cells destined to die during the contraction phase of
the immune response or a few may divert to become memory
T cells (Ahmed et al., 2009). TCR triggering initiates CTL differen-
tiation and sustained IL-2 signaling promotes effector CTL differ-
entiation. The present data now show that the ability of these
receptors to sustain Akt activity is needed to maintain the tran-
scriptional program of CTL. In particular, Akt signaling maintained
CTL effector function and controlled expression of multiplearison of the transcriptional profile in control versus AktI-treated cells was then
ging in expression after Pdpk1 loss but not Akt inhibition.
t not Akt inhibition.
nes that are significantly different in expression between untreated and AktI-
ontrol versus Pdpk1-null CTL, (E) untreated versus 48 hr AktI-treated wild-type
) untreated versus 48 hr IC87114-treated CTL.
al replicates.
Figure 5. Suppression of PI3K p110d and Akt Reprograms Lymph Node Homing of CTL
(A) Heat map showing the relative normalized expression of selected genes that are significantly different in expression between untreated and AktI-treated CTL,
as determined by microarray.
(B) Lymph node P14 T cells were activated for 2 dayswith cognate peptide and then cultured for 5 days in IL-2, with IC87114 being added to half of each culture for
the last 48 hr. Cells were then labeled with carboxyfluorescein succinimidyl ester (CFSE) or 5-(and-6) (((4chloromethyl)benzoyl) amino) tetramethylrhodamine
Immunity
Akt Transcriptional Programs in Cytotoxic T Cells
Immunity 34, 224–236, February 25, 2011 ª2011 Elsevier Inc. 231
Immunity
Akt Transcriptional Programs in Cytotoxic T Cellsbiomarkers that distinguish central memory T cells from effector
T cells. The loss of Akt activity thus reprogrammedCTL to assume
a ‘‘memory-naive’’ phenotype by synchronizing a decrease in the
expression of cytolytic effector molecules such as perforin and
IFN-g while causing an increase in expression of genes encoding
the cytokine receptors for IL-6 and IL-7 along with tumor necrosis
factor receptor family member CD27. These latter molecules all
play key roles in the homeostasis and survival of long-lived
memory CD8+ T cells (Castellino and Germain, 2007; Hendriks
et al., 2003; Kaech et al., 2003). Akt also controlled the repertoire
of chemokine and adhesion molecules expressed by T cells that
define whether these cells can traffic to secondary lymphoid
tissue and progress tomemory cells. Importantly, Akt inhibition al-
lowed CTL to reacquire the ability to home to secondary lymphoid
tissue. Collectively, these results reveal that sustained Akt
signaling is required to maintain CTL effector function; the loss
or reduction of Akt signaling does not impact T cell survival or
proliferation but causes differentiated CTL to transcriptionally
reprogram from an effector to a memory phenotype. Hence the
simple viewof Akt as ametabolic regulator is likely to be incorrect;
rather, in CTL the role of Akt is to control the transcriptional
programs that direct effector versus memory T cell fate. In
particular, the data regarding Akt and T cell migration afford an
explanation for the defects in the ability of antigen-primed PI3K
p110d-deficient T cells in vivo tomigrate to antigenic sites (Jarmin
et al., 2008; Liu and Uzonna, 2010). The data also argue that the
in vivo role of IL-2 to sustain effector CTL function may rely on
Akt-dependent expression of differentiation and trafficking
molecules.
Finally, an emerging concept in T cell biology is that limiting
T cell metabolism may accelerate the conversion of effector
CTL into a memory subset (Araki et al., 2009; Pearce et al.,
2009; Prlic and Bevan, 2009). This idea was based on studies
linking mammalian target of rapamycin (mTOR) and adenosine
monophosphate-activated protein kinase (AMPK) to the produc-
tion of memory T cells during an immune response (Araki et al.,
2009; Pearce et al., 2009; Rao et al., 2010). AMPK and mTOR
are known to regulate cell metabolism but it was not directly
proven that the role of either enzyme was caused by effects on
T cell metabolism. The role of Akt in CTL suggests an alternative
possibility: enzymes that originally evolved to control cell metab-
olism have evolved the ability to control other aspects of T cell
function and can do so independently of effects on T cell
metabolism.
EXPERIMENTAL PROCEDURES
Mice
C57BL/6GT(ROSA)26tm9(creEsr1)Arte (TamoxCre) mice were obtained from Ta-
conic Artemis Pharmaceuticals.Mice carrying floxedPdpk1 allelesPdpk1flDneo
(PDK1fl); OT1 and P14 TCR transgenic mice; P14 TCR transgenic mice
carrying a knockin mutation for a substitution of lysine for glutamic acid at(CMTMR) andmixed at a ratio of 1:1 before being injected into C57/BL6 host mice
of the total recovered transferred cells from the blood and lymph nodes 18 hr aft
(C) As for (B) with cells being treated with AktI rather than IC87114 for the last 48
(D–F) CD8+ T cells expressing Va2Vb5 TCR were purified from Pdpk1WT/WT OT
a 1:1 ratio, and stained with CFSE. 5 3 106 mixed T cells were injected into the
intraperitoneally with either 25 mg LPS or LPS plus 40 mg of SIINFEKL peptide.
nodes and proliferation (CFSE dilution) was analyzed after 6 days, with CD62L e
232 Immunity 34, 224–236, February 25, 2011 ª2011 Elsevier Inc.residue 465 in the PHdomain of PDK1 (Pdpk1K465E) andPik3cdD910Amice con-
taining a knockin mutation of PI3K wherein wild-type alleles of the p110d cata-
lytic subunit of PI3K were substituted with a point mutation (D910A), which is
a catalytically inactive form of p110d (p110dD910A), have been described (Kelly
et al., 2007; Kurts et al., 1996; Pircher et al., 1989; Waugh et al., 2009). Mice
were produced in the Biological Resource Unit at the University of Dundee
in compliance with UK Home Office Animals (Scientific Procedures) Act
1986 guidelines.
Cell Culture
CD8+ T cells were isolated from spleens and/or lymph nodes with an Auto-
MACs magnetic cell sorter (Miltenyi Biotec). Lymphocytes were suspended
in RPMI 1640 plus 10% heat-inactivated fetal calf serum (FCS), penicillin,
streptomycin (GIBCO), and 50 mM b-mercaptoethanol (b-ME) (Sigma) and acti-
vated for 48 hr in either 0.5 mg/ml CD3 antibody (2C11) or 100 ng/ml LCMV
TCR-specific peptide gp33-41, KAVYNFATM. Cells were then washed free
of activating agent and thereafter maintained in 20 ng/ml IL-2 at a density of
approximately 0.3 3 106/ml at 37C, 5% CO2. 4-hydroxytamoxifen (4OHT,
Sigma) was used at 0.6 mM. AktI-1/2 (AktI) (Calbiochem) was used at 1 mM,
the p110d inhibitor IC87114 (made in-house) and LY294002 (Promega) were
used at 10 mM. Where indicated cells were cultured in media of defined
glucose concentrations with glucose-free RPMI containing L-glutamine
(GIBCO) with 10% dialyzed FCS (GIBCO), penicillin, streptomycin, 50 mM
b-ME (glucose-free media) plus D(+)glucose (Sigma). Pdpk1-deleted CTL
were prepared by activating Pdpk1fl/fl TamoxCre splenocytes with 2C11 for
2 days and then culturing the cells in IL-2 for 5 days, with 0.6 mM 4OHT being
added for the final 72 hr of culture.
Flow Cytometry
Cells were labeled in RPMI plus 0.5%FCSwith Phycoerythrin-conjugated anti-
CD62L, Alexa750-conjugated anti-CD4, PerCP.Cy5.5-conjugated anti-TCR
Va2, allophycocyanin-conjugated anti-CD45.2, Horizon V450-conjugated
anti-CD45.1, and phycoerythrin.Cy7-conjugated anti-CD8. For FoxoAAA,
IFN-g double-staining cells were stimulated in the presence of 3 mg/ml Golgi-
plug (BD), fixed and permeabilized as per manufacturer’s instructions
(eBioscience 00-8222-49, 00-8333-56), and then stainedwith Alexa488-conju-
gated anti-GFP (Invitrogen) plus allophycocyanin-conjugated anti-IFN-g (BD
Biosciences). Data were acquired on a FACS Calibur (BD Biosciences) and
analyzed with FlowJo software (Treestar). Viable cells were gated according
to their forward scatter (FSC) and side scatter (SSC) profiles. GFP+/ cell isola-
tion was performed with a Vantage cell sorter (BD Biosciences).
Immunoblot Analysis
Cells were lysed on ice in HEPES lysis buffer: 100mMHEPES (pH 7.4), 150mM
NaCl, 20 mMNaF, 20mM iodoacetamide, 2 mM EDTA, 1%NP-40, 1 mM phe-
nylmethylsulfonyl fluoride, 1 mM sodium orthovanadate, 40 mM b-glycero-
phosphate (Sigma), and protease inhibitors (Roche). Lysates were centrifuged
(4C, 1600 3 g, 15 min) and then samples separated via sodium dodecyl
sulfate 4%–12% polyacrylamide gel electrophoresis and transferred to nitro-
cellulose membranes. Blots were probed for pT24 Foxo1 + p32Foxo3a;
pT308 and total Akt; pT235 + pT236 and total small ribosomal subunit S6;
pS389, pS421 + pS424, and total S6K; PKCq (all Cell Signaling Technologies);
pS227 p90RSK (Santa-Cruz Biotechnology); total Foxo3a (made in house);
PDK1 (Upstate); or perforin (gift of G. Griffith).
Glucose and Phenylalanine Uptake
1 3 106 cells were suspended in 500 ml glucose-free media for 10 min. 500 ml
glucose-free media containing 1 mCi/ml 2-Deoxy-D-[1-3H]glucose ([3H] 2DOG)
(GE healthcare) was then added and the cells incubated for a further 10 min.. Values indicate recovery of inhibitor-treated or untreated cells as a percentage
er transfer. Each dot indicates a mouse; horizontal bars indicate mean.
hr of culture.
1 (CD45.1+/+) and Pdpk1K465E/K465E OT1 (CD45.1+ CD45.2+) mice, mixed at
tail vein of C57/BL6 mice (CD45.2+/+). 24 hr later the host mice were injected
The ratio of Pdpk1WT/WT OT1 and Pdpk1K465E/K465E OT1 donor cells in lymph
xpression assayed after 2, 4, and 6 days.
Figure 6. Suppression of PI3K p110d and Akt Alters the Expression of Key CTL Effector Molecules
(A and B) Heat maps showing the relative normalized expression of selected genes that are significantly different in expression between untreated and AktI-
treated CTL, as determined by microarray.
(C) Wild-type splenocytes were activated with 2C11 for 48 hr with IL-2 and then cultured in IL-2 for a further 5 days, with half the cells being placed in AktI for the
last 48 hr of culture. Shown is IFN-g release by 1 million cells in 6 hr, relative IFN-g mRNA content, immunoblot analysis of total perforin protein content, and
perforin mRNA content of cells cultured with and without AktI.
(D) Pdpk1-null (Pdpk1fl/fl/ tm9(creEsr1)Arte +4OHT) and Cre control (Pdpk1+/+/ tm9(creEsr1)Arte +4OHT) CTLwere generated. Shown are IFN-g release by 1million cells in
6 hr, relative IFN-g mRNA content, immunoblot analysis of total perforin protein content, and perforin mRNA content of Cre control versus Pdpk1-null CTL.
Data representative of a minimum of three experiments; mean ± SEM of biological replicates.
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was then measured via liquid scintillation counting. For phenylalanine uptake,
the assay was performed essentially as for glucose uptake, except that assayswere performed in HBSS, 50 mM b-ME, 13MEM vitamins (GIBCO), with 10%
dialyzed FCS. [3H]Phe (GE Healthcare) was added and cells incubated for 1 hr
prior to pelleting.Immunity 34, 224–236, February 25, 2011 ª2011 Elsevier Inc. 233
Figure 7. PDK1 Controls Antigen Receptor-Driven IFN-g Expression via a Foxo-Mediated Mechanism
(A) Naive P14 lymph node T cells were stimulated for 4 hr with LCMV peptide gp33 in the presence or absence of AktI and the IFN-g produced assayed by ELISA.
(B) P14 T cells were activated for 48 hr with gp33 and then cultured for 3 days in IL-2. Left: Cells were then stimulated for 4 hr with 100 ng/ml gp33 in the presence
of AktI or IC87114 and IFN-g production assayed by flow cytometry. Right: Alternatively, cells were stimulated for 4 hr with 125 ng/ml gp33 in the presence of AktI
and IFN-g production assayed by ELISA.
(C) P14 T cells were activated for 48 hr with gp33 and then cultured for 3 days in IL-2. Cells were stimulated for 3 hr with 62.5 ng/ml gp33 in the presence or
absence of AktI. ChIP was performed with anti-PolII, and the changes in PolII binding to (left) the IFN-g-proximal promoter region and (right) the IFN-g fourth
exon were quantified by real-time PCR. Data are normalized to input DNA amounts and plotted as fold over the values for PolII binding to the HPRT-proximal
promoter.
(D) P14 TCR transgenic T cells from lymph nodes of Pdpk1WT/WT and Pdpk1K465E/K465E P14 transgenic mice were activated for 48 hr with gp33 and then cultured
for 3 days in IL-2. Cells were then stimulated for 4 hr with gp33 and IFN-g produced assayed by ELISA.
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RNA was extracted from cells with the RNeasy RNA purification minikit
(QIAGEN). Reverse-transcription PCR was performed with qScript cDNA
synthesiskit (Quanta).Real-timePCRwasperformedwith iQSYBRGreendetec-
tion chemistry (BioRad) on an iCycler (BioRad). RelativemRNA levels of genes of
interest were normalized to hypoxanthine guanine phosphoribosyltransferase
(HPRT). Primers are detailed in the Supplemental Experimental Procedures.
ChIP
Real-time PCR-based chromatin immunoprecipitation (ChIP) analysis to
measure RNA Pol II binding to the IFN-g locus was performed described
(Cruz-Guilloty et al., 2009) with minor modifications. Chromatin was immuno-
precipitated with anti-Pol II (Santa-Cruz Biotechnology) or normal rabbit IgG
(Cell Signaling) from 5 3 106 cells in presence of 0.2 mg/ml BSA. ChIP Grade
Protein G Magnetic Beads (Cell Signaling) were used to collect the immuno-
complexes. Chromatin was purified via a NucleoSpin Extract II kit (Ma-
cherey-Nagel) and resuspended in TE buffer. Real-time PCR was performed
in a Biorad iQ5with Perfecta SYBR green FastMix for iQ (Quanta BioSciences).
Primers are detailed in the Supplemental Experimental Procedures.
Retroviral Transduction
The production of FoxoAAA-GFP (Foxo3a T32A S252A S314A) and control
retrovirus has been described previously (Waugh et al., 2009). The retroviral
infection protocol was performed as described previously (Waugh et al., 2009).
IFN-g Quantification
IFN-g was assayed in culture supernatants with the femto-HS high-sensitivity
IFN-g ELISA kit (eBiosciences).
Microarray Analysis
Microarray analysis was carried out by the Finnish DNA Microarray Centre at
the Centre for Biotechnology, Turku, Finland via 430_2.0 mouse expression
arrays (Affymetrix) and the manufacturer’s recommended protocol. Statisti-
cally significant differences in gene expression were identified with Multiple
Experiment Viewer v4.3 (Saeed et al., 2003). Overrepresented gene ontology
terms were identified with the NIAID DAVID website (http://www.david.abcc.
ncifcrf.gov). Full details are given in Supplemental Experimental Procedures.
Statistical Analyses
With the exception of the microarray data, statistical analyses were performed
with Prism 4.00 for Macintosh (GraphPad). A nonparametric Mann Whitney
test was used where the number of experiments performed was not sufficient
to prove normal distribution. Statistically significant results (p < 0.05) are indi-
cated by an asterisk.
ACCESSION NUMBERS
The microarray data are available in the Gene Expression Omnibus (GEO)
database (http://www.ncbi.nlm.nih.gov/gds) under the accession number
GSE26290.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures,
one figure, and three tables and can be found with this article online at
doi:10.1016/j.immuni.2011.01.012.
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